According to Houston-based ENGlobal, the company "has more promising opportunities for significant new business than at any time in [the] company's history." Photo via Getty Images

For Houston-based ENGlobal Corp., a provider of engineering and automation services geared toward the energy industry, renewable fuel facilities are a business pipeline gushing with opportunity.

ENGlobal's potential contracts for renewable fuels projects currently exceed $320 million, says Bill Coskey, the company's founder, president, and CEO. That's about six times the amount of ENGlobal's revenue through the first nine months of this year — $52.9 million.

During the company's third-quarter earnings call November 5, Coskey said publicly traded ENGlobal "has more promising opportunities for significant new business than at any time in our company's history."

Many of those opportunities stem from ENGlobal's shift a couple of years ago to a sharp focus on the renewable energy sector. This includes building utility-scale systems to store wind and solar power, and supplying modular engineered process plants for forms of energy like hydrogen and renewable diesel. Modular process plants consist of separately engineered and automated modules that are made off-site and assembled on-site.

"Manufacturing plants based on modular equipment are emerging as a viable and beneficial alternative to conventional stick-built processing plants. Modular equipment offers several benefits, including flexibility in plant siting, fewer safety concerns during construction, and ease of equipment modification," according to the American Institute of Chemical Engineers.

ENGlobal is engineering and fabricating a modular hydrogen plant for a renewal diesel facility scheduled for completion in May. Incorporating proprietary technology from Denmark-based Haldor Topsoe (which has two offices and one plant in the Houston area), this hydrogen plant will consume about 20 percent less feed and fuel than conventional hydrogen plants, leading to lower operating costs and a smaller carbon footprint. It's the first facility of its kind in the U.S. This $25 million project falls into a bucket of modular process plants — valued at $10 million to $200 million each — that ENGlobal typically pursues.

ENGlobal's emphasis on renewable energy is paying off, especially now. That's because this sector is less susceptible to economic harm caused by the coronavirus pandemic and to the downturn in the oil and gas industry, according to Coskey.

"To the contrary, the green and renewable energy sector is driven by a different set of project economics — the majority of which play directly to our core strengths and capabilities," Coskey said during the November 5 earnings call.

ENGlobal comprises two business units that are capitalizing on those core strengths and capabilities:

  • Engineering, procurement, and construction management
  • Automation

Through September 26, the automation segment of the business accounted for 63 percent of the company's revenue this year, with engineering, procurement, and construction at 37 percent. In the third quarter, the balance was roughly 50-50.

For the nine-month period ended September 26, ENGlobal posted a 33 percent increase in revenue compared with the same period a year earlier. Revenue for the period rose 37 percent in the automation segment of the business and 27 percent in the engineering, procurement, and construction management segment.

Looking ahead, Coskey says plants like the one employing the Haldor Topsoe technology are "a big area of growth for us."

"We've built a business which is really vertically integrated. We can engineer and design, we can mechanically fabricate the processing modules, we can automate them, we can go onto the site and start them up. So we have full-service capabilities," Coskey says in an interview.

Those capabilities are helping ENGlobal, which Coskey started in 1985, capitalize on what he dubs the "energy revolution" in the U.S.

"Oil and gas has a long runway and is sometimes not given enough credit," he says. "But I can tell you that the capital spending for traditional oil and gas projects pretty much dried up during the course of this year. And we had to look for other sources of work for our people, so we were fortunate to have these renewable energy projects to work on."

Evercore ESI predicts capital spending on energy exploration and production in the U.S. will fall 43 percent this year compared with 2019. Meanwhile, S&P Global Market Intelligence forecasts $14.26 billion in capital spending this year on renewable energy by major U.S. utilities, up more than 20 percent from an earlier projection for 2020. The share of U.S. electricity generation from renewable energy is expected to increase from 18 percent in 2019 to 20 percent this year and 21 percent in 2021, the U.S. Energy Information Administration says.

"There's a lot of money that used to flow into oil and gas projects that now seems to be flowing into renewable energy projects," Coskey says. "We were lucky to identify that early and be positioned to capture some of that."

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Houston researchers report promising first in-human trial for implantable cancer therapy

cancer breakthrough

When it comes to cancer remedies, the treatment can be as challenging for the body as its cause. But what if immunotherapy could be localized? That’s precisely what a Houston team may soon make a reality.

Rice University researchers, in partnership with MD Anderson Cancer Center, recently published their findings from the first in-human trial of an implantable cancer-fighting treatment in the journal Clinical Cancer Research. The paper details testing of AVB-001, encapsulated cells engineered to release interleukin-2 (IL-2)—a naturally occurring signaling protein that boosts immunity—in the peritoneal cavities of 14 patients. The goal is to avoid the toxicity usually experienced with less targeted treatments, as well as find a solution to IL-2s’ abbreviated half-lives.

“Traditional IL-2 therapy has shown potent antitumor activity, but its clinical use has been limited by severe side effects and delivery challenges,” Omid Veiseh, director of the Rice Biotech Launch Pad, professor of bioengineering at Rice and a senior author on the study, said in a press release. “This platform allows us to localize and sustain cytokine exposure directly where tumors reside while minimizing systemic toxicity.”

Serous ovarian carcinoma is especially well-suited to the use of AVB-001 because it tends to spread throughout the abdomen. After a minimally invasive laparoscopic procedure, patients implanted with the cells were noted to tolerate the treatment well. Half of the enrolled patients’ cancer was stabilized, with several among them reporting extended signs of benefit. No maximum tolerated dose was reached and there were no life-threatening events tied to the study.

If that sounds like less-than-earth-shaking results, this is only the beginning. The capsules were implanted for about one week because IL-2 activity drops off after that. The researchers now know that further testing should include either higher levels, repeated doses, or a combination thereof, in order to create stronger advances.

The team has already made early headway on this next step. Preclinical studies in nonhuman primates were not only tolerated well, but without added toxicity, the apes had consistent pharmacological effects.

“This is a foundational step,” Veiseh explained. “We now have evidence that the platform is safe, biologically active and potentially scalable. The next phase is optimizing dosing and exploring combination therapies to unlock its full clinical potential.”

The combination would also include a checkpoint inhibitor, which might improve AVB-001’s tumor-fighting power. “What is exciting is that we are not just delivering a drug, we are programming a microenvironment,” added Dr. Amir Jazaeri, professor of gynecologic oncology at MD Anderson, member of the Rice Biotech Launch Pad’s clinical advisory board and a senior author on the study. “This opens the door to combination strategies that could amplify immune responses in ways that have not been feasible before.”

Houston startup raises $6M to scale home-based healthcare platform

fresh funding

As healthcare systems race to expand care beyond hospitals and into the home, investors are placing bigger bets on the infrastructure needed to make that shift possible.

This month, Rosarium Health announced it has raised $6 million in seed funding led by Kalos Ventures, with participation from ResilienceVC, Rock Health Capital, Symphonic Capital, Black Tech Nations Ventures and others.

The investment will help the Houston-based startup continue to build its platform, which features a national network of 800-plus clinicians and 3,000-plus contractors to coordinate home accessibility upgrades and modifications for seniors and people living with disabilities.

For founder and CEO Cameron Carter, the company’s mission grew out of firsthand caregiving experiences.

“From my own personal caregiving experiences, I realized that the benefits exist on paper, but not in reality,” Carter said in a news release. “Families are being left to figure out the paperwork and installations all on their own, which shouldn’t be how this works.”

While Medicare Advantage and Medicaid plans have expanded coverage for home-based services and accessibility modifications, the logistics behind delivering those services often remain fragmented.

Rosarium’s platform coordinates the entire process, from clinical assessments and referrals to contractor management, documentation, reimbursement and installation.

“A clinician can document that a home isn’t safe and a plan can approve a benefit, but there’s no one that’s responsible for making sure the work actually gets done,” Carter says. “We built the missing piece.”

The company was founded in 2021 as Rose Health and was a 2023 participant in the Texas Medical Center’s Accelerator for HealthTech program. It has scaled quickly, building a network of more than 800 clinicians and 3,000 contractors across 34 states.

Rosarium is currently in-network for 1.2 million Medicare and Medicaid lives, with projected coverage expected to reach nearly 4 million by the end of the year, according to the release.

“We’re excited to back Cameron because he and the team at Rosarium are building the infrastructure healthcare needs right now to make the home a safe and comfortable place of care,” Kate Ballinger, investor at Kalos Ventures, added in the release.

As part of the recent investment, Ballinger will join Rosarium’s board of directors.

With eyes on the future, Rosarium plans to grow its partnerships with Medicaid and Medicare Advantage plans, including CalViva and Community Health Plan of Imperial Valley, strengthening its presence in California while expanding access to underserved communities.

Additionally, Carter predicts that home-based healthcare will be part of a broader transformation happening across the industry.

“There’s a growing recognition that health outcomes are shaped by what happens in the home,” he said in the release. “The future of healthcare isn’t just treating people after something goes wrong. It’s creating environments that help prevent those problems in the first place.”